Japan's responsible and proactive fiscal policy will be positive for the economy and the yen, Growth Strategy Minister Minoru Kiuchi said in an Bloomberg TV interview with Shery Ahn in Tokyo.
Embraer (NYSE:EMBJ) reported Q2 2026 revenue of $2.235 billion, up 23% year over year, as aircraft deliveries increased and firm order backlog reached a record $34.5 billion.
AirSculpt Technologies (NASDAQ:AIRS) reported Q2 2026 revenue of $42.9 million, down 3%, while case volume declined 0.5% to 3,376 procedures and adjusted EBITDA fell to $4.9 million.
BeOne Medicines (NASDAQ:ONC) and Revolution Medicines (NASDAQ:RVMD) announced a multi-part oncology collaboration combining clinical research programs with a regional rights agreement covering four RAS(ON) inhibitors in selected Asian markets.
Dole (NYSE:DOLE) reported Q2 2026 revenue of $2.499 billion, up 2.9%, while net income increased to $35.1 million from $18 million.
ChipMOS Technologies (NASDAQ:IMOS) reported unaudited July 2026 revenue of NT$2.823 billion (US$87.5 million), up 43.6% year over year and 11.2% sequentially.
National Energy Services Reunited (NASDAQ:NESR) reported Q2 2026 revenue of $520.8 million, up 59.1% year over year, while net income increased to $44.0 million.
Mining entrepreneur Robert Friedland discusses his backing of Sunrise Energy Metals Ltd., an Australian scandium miner which secured as much as $400 million in long-term debt financing from the US Department of War. He speaks on Bloomberg Television.
Markets are poised for a slight uptick in US inflation this week, along with cooling economic expansion in the UK. Bloomberg's Morwenna Coniam speaks to Tom Mackenzie and Guy Johnson on 'Bloomberg: The Opening Trade.'
TSMC reported a 45% rise in its monthly sales, a sign of sustained demand for AI hardware in the face of market volatility. Bloomberg's Neil Campling has more.
Barrick Mining (NYSE:B) reported Q2 2026 revenue of $5.29 billion, up 44% year over year, while expanding its Nevada Gold Mines joint venture with Newmont through a revised ownership structure.
Innate Pharma (NASDAQ:IPHA) announced plans to begin the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma, subject to completion of its strategic partnership with Sobi.
